
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CCL14 CRISPR/Cas9 KO Plasmid (h) | sc-406423 | 20 µg | $397.00 |
CCL14 encodes a secreted CC chemokine that helps coordinate leukocyte trafficking by engaging chemokine receptors on monocytes, lymphocytes, and other immune cell subsets, thereby shaping inflammatory gradients and immune cell positioning within tissues. As part of the broader chemokine network, CCL14 contributes to chemotaxis, modulation of cytokine signaling, and cross-talk with pathways governing endothelial activation and extracellular matrix remodeling. Dysregulated chemokine signaling involving CCL14 has been linked to altered immune infiltration patterns observed in chronic inflammatory states and tumor-associated inflammation, where shifts in chemokine cues can influence immune surveillance and stromal interactions. Accordingly, CCL14 is frequently studied in contexts such as immune cell migration assays, inflammatory signaling profiling, and systems-level mapping of chemokine networks.
CCL14 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CCL14 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CCL14 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CCL14 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CCL14 protein expression.
This CRISPR knockout system enables efficient generation of CCL14-deficient cell models for investigation of CCL14 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.